Does Menopause Make You Tired? Fatigue Causes and Tips for More Energy

Menopause-related fatigue is common, and it usually stems from a combination of vasomotor symptom-driven sleep fragmentation, hormonal changes affecting mood and metabolism, and overlapping treatable conditions such as hypothyroidism, iron deficiency, and low vitamin D. There is no laboratory test for "menopause fatigue" as such; it is best understood as a diagnosis reached after ruling out other treatable causes. For women with confirmed hot flashes or night sweats, hormone therapy or the non-hormonal medication fezolinetant can reduce vasomotor symptoms and improve sleep, but neither is FDA-approved as a direct fatigue treatment, and fatigue that does not track with vasomotor symptoms deserves its own workup.

What "menopause" and "perimenopause" mean here

Menopause is defined clinically as 12 consecutive months without a menstrual period, marking the end of ovarian egg release and a sustained drop in estrogen and progesterone production. Perimenopause is the transition leading up to that point, often lasting several years, during which hormone levels fluctuate rather than fall steadily. Most of the fatigue-related symptoms people associate with "menopause," including hot flashes, night sweats, and mood changes, actually begin during perimenopause and can continue for some time after the final period.

This matters for treatment decisions because a woman who is still cycling irregularly (perimenopause) and a woman who is several years past her final period (postmenopause) may need different diagnostic priorities, even though both can experience similar fatigue.

Why fatigue shows up during this transition

Estrogen and progesterone influence more than reproduction. Estradiol has documented effects on mood-regulating neurotransmitter systems, on the body's stress-response axis, and on sleep regulation. Progesterone is metabolized into allopregnanolone, a compound that acts on GABA receptors and is thought to support deeper, more restorative sleep. As levels of both hormones decline and fluctuate through the menopause transition, several systems that support daytime energy are affected at once. This is a plausible and widely accepted physiological explanation, but it is a mechanism, not a guarantee that every case of fatigue in a perimenopausal woman is hormonal. Overlapping conditions common at this age need to be excluded before fatigue is attributed to hormones alone.

Hot flashes, night sweats, and disrupted sleep

Vasomotor symptoms, the clinical term for hot flashes and night sweats, are the most direct link between menopause and daytime fatigue. They occur because falling and fluctuating estrogen narrows the brain's thermoregulatory tolerance zone, so small shifts in core body temperature trigger sweating and flushing that would not have caused a reaction before. When these episodes happen overnight, they interrupt sleep, often repeatedly, and repeated awakenings prevent the deeper, slow-wave sleep stages associated with physical recovery.

Women who experience frequent night sweats commonly describe daytime fatigue that feels heavier than their activity level would predict, and that pattern is consistent with sleep fragmentation rather than sleepiness from a single bad night. Smaller trials have linked higher frequency of hot flashes to worse fatigue and sleep-quality scores, though exact effect sizes vary between studies and should be treated as suggestive rather than fixed figures.

Could it be your thyroid instead?

Thyroid dysfunction, especially hypothyroidism, becomes more common with age, and its symptoms overlap heavily with menopause: fatigue, weight gain, cold intolerance, slowed thinking, and mood changes. Because the two conditions can occur in the same woman at the same time, clinicians are encouraged to check thyroid function rather than assume symptoms are hormonal by default.

A few features can help distinguish the two, though neither is definitive on its own. Hypothyroid fatigue tends to be present on waking regardless of how the previous night's sleep went, while menopause-related fatigue often tracks closely with the previous night's vasomotor symptoms. A TSH level, paired with free T4 if TSH is abnormal, is the standard first step. Subclinical hypothyroidism, where TSH is mildly elevated but free T4 is still normal, is a judgment call that a clinician should make based on symptoms and risk factors, not something to self-diagnose or self-treat.

Anemia, iron deficiency, and B12: overlooked in perimenopause

Perimenopause frequently brings heavier or more irregular periods before cycles stop entirely, and heavy bleeding raises the risk of iron deficiency. Iron deficiency is a well-documented and common cause of fatigue in women of reproductive age generally, according to CDC surveillance data on anemia in the United States. (CDC, MMWR) Because a standard complete blood count can miss early iron deficiency, a ferritin level is a more sensitive way to check iron stores when fatigue is heavy bleeding-associated.

Vitamin B12 absorption can also decline with age, particularly if atrophic gastritis reduces production of intrinsic factor, the protein needed to absorb B12 in the gut. Fatigue with a low-normal or low B12 level warrants further evaluation and supplementation guided by a clinician, not empiric high-dose self-treatment, since B12 deficiency can also signal other absorption problems worth investigating.

Vitamin D and energy: plausible but not the whole story

Low vitamin D is associated with fatigue in observational data, and postmenopausal women are at somewhat higher risk of deficiency due to reduced skin synthesis with age and changes in calcium-vitamin D receptor signaling after estrogen loss. Some small randomized trials have found that correcting a confirmed deficiency improves fatigue scores, but the trial base is limited, and vitamin D repletion should be guided by an actual blood level rather than taken as a general energy supplement. A level below 20 ng/mL is generally considered deficient; general guidance for adults commonly targets levels above 30 ng/mL, though the exact target and dosing should come from a clinician who has seen your result, not a blanket protocol.

What hormone therapy can and cannot do for fatigue

Estrogen therapy, with a progestogen added for women who still have a uterus, is FDA-approved for moderate-to-severe vasomotor symptoms and remains the most effective treatment for hot flashes and night sweats. Because it treats the sleep disruptor directly, women who start hormone therapy for vasomotor symptoms often report improved sleep and, secondarily, less fatigue. That said, hormone therapy is not FDA-approved as a fatigue treatment in its own right, and it will not meaningfully help fatigue that is driven by something else, such as untreated hypothyroidism or depression.

Micronized progesterone is sometimes favored over synthetic progestins when sleep is a priority, based on its conversion to allopregnanolone and its GABA-related sedative effect, though head-to-head evidence comparing formulations for sleep outcomes specifically is limited and worth discussing with a prescriber rather than assuming one option is automatically better.

Hormone therapy is not appropriate for every woman. Contraindications include unexplained vaginal bleeding, active liver disease, a personal history of estrogen-receptor-positive breast cancer, and a history of venous thromboembolism, among others. Transdermal estrogen is generally considered to carry a lower clotting risk than oral formulations, which is one reason route of administration is part of the shared decision with a clinician. The Menopause Society's hormone therapy guidance is a useful primary reference for weighing benefits against risks by age and time since menopause, and it should be reviewed directly rather than through a paraphrase when making a treatment decision.

Non-hormonal medication options

Fezolinetant (brand name Veozah) is a neurokinin 3 receptor antagonist that the FDA approved in 2023 specifically for moderate-to-severe vasomotor symptoms in women who either prefer not to use hormone therapy or cannot use it. Clinical trials reported meaningful reductions in hot flash frequency; readers considering this option should review current FDA prescribing information for up-to-date efficacy and safety data, since label details can change.

SSRIs and SNRIs, including venlafaxine, are used off-label for hot flashes in women who cannot or prefer not to use hormone therapy. This is an off-label use for vasomotor symptoms, distinct from their FDA-approved use for depression and anxiety, and it should be discussed as such with a prescriber.

Exercise, sleep habits, and diet: what the non-drug evidence supports

Regular aerobic activity and resistance training are consistently associated with better energy and mood in midlife women across observational and trial data, and general physical activity guidelines (150 minutes per week of moderate aerobic activity, plus muscle-strengthening activity) apply here as they do for adults generally. Resistance training two or more times per week may help offset the loss of muscle mass that tends to accelerate around menopause, which can otherwise make everyday activity feel more effortful.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia recommended by sleep medicine guidelines, for adults broadly, including menopausal women whose insomnia persists after vasomotor symptoms are treated. It typically outperforms sleep medication on longer follow-up and does not carry the dependency risk of sedative-hypnotics.

On diet, a Mediterranean-pattern diet emphasizing vegetables, fiber, lean protein, and healthy fats is associated with lower inflammatory markers and is a reasonable general recommendation, though the evidence specifically tying it to menopausal fatigue (rather than cardiovascular or metabolic outcomes) is less direct. Soy isoflavones have been studied for hot flash reduction with modest and inconsistent results across meta-analyses; they are not a substitute for hormone therapy in women with significant symptoms, and anyone with a history of hormone-sensitive cancer should discuss isoflavone supplements with their oncology team before use.

Mood, fatigue, and when they overlap

Fatigue and depressive symptoms frequently co-occur during perimenopause, and the direction of cause and effect is often unclear in an individual case: poor sleep can worsen mood, and low mood can worsen fatigue and sleep together. A PHQ-9 questionnaire is a quick, validated way to screen for depression severity, and a score of 10 or higher is generally considered a threshold for discussing treatment with a clinician. Mindfulness-based approaches have shown some benefit for stress and fatigue in small trials and can be a reasonable adjunct, but they are not a substitute for treating moderate-to-severe depression.

What labs to ask about before assuming it's "just menopause"

A basic panel helps separate menopause-related fatigue from other treatable causes, and it is reasonable to request before committing to a hormone-therapy trial or a supplement regimen:

• TSH and free T4
• CBC with differential
• Ferritin (drawn separately from a standard CBC)
• 25-hydroxyvitamin D
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• FSH and estradiol, if confirming menopausal status is clinically useful
• Morning cortisol, only if adrenal insufficiency is specifically suspected

Fatigue that persists despite normal labs and that tracks closely with hot flashes and poor sleep is more likely to be primarily menopause-related and to respond to vasomotor symptom treatment, exercise, and sleep-focused strategies.

A decision framework: matching your fatigue pattern to the next step

Because "menopause fatigue" is really several possible problems wearing one label, the most useful next step depends on which pattern fits. This is a general decision aid, not a diagnostic tool, and it does not replace a clinical visit.

What is established, what is plausible, and what is not settled

Established: menopause and perimenopause are associated with a real increase in reported fatigue for many women, largely mediated through vasomotor symptoms and their effect on sleep. Hormone therapy is FDA-approved and effective for reducing vasomotor symptoms, and fezolinetant is an FDA-approved non-hormonal alternative for the same indication. Thyroid disease, iron deficiency, and depression are common, treatable conditions that can mimic or compound menopause fatigue and should be checked for rather than assumed away.

Plausible but not firmly established: that correcting vitamin D, magnesium, or CoQ10 levels produces a meaningful, durable improvement in fatigue in women who are not clearly deficient. That specific supplement doses (rather than dose ranges guided by lab values) produce predictable benefit. That diet pattern alone, independent of weight and activity changes, meaningfully changes fatigue scores in this population.

Not established from the evidence reviewed here: that any single medication or supplement treats "menopause fatigue" as its own condition, independent of treating an underlying driver such as vasomotor symptoms, thyroid disease, or a nutrient deficiency.

When to seek care sooner rather than later

Fatigue that interferes with work, relationships, or daily function for more than two weeks deserves a clinical evaluation, as does fatigue accompanied by chest pain, palpitations, significant unintentional weight change, or fainting. These symptoms are not typical of menopause alone and warrant prompt assessment rather than a trial of lifestyle changes first.